Correcting post‐keratoplasty anisometropia with the implantable collamer phakic intraocular lens

Background: We evaluate the Visian Implantable Collamer Lens (Staar, Monrovia, CA, USA) phakic intraocular lens for treating post‐keratoplasty anisometropia. Methods: Case series of three eyes (2 phakic and 1 pseudophakic). Results: The mean age was 47.3 years (range 30–73 years), with a minimum of 3‐month follow up. The mean preoperative spherical equivalent was ?8.75 ± 5.17 D (?4.00 to ?14.25 D) improving to ?0.29 ± 1.21 D postoperatively (range 0.75 to ?1.625 D). Mean logMAR uncorrected visual acuity improved from 1.66 ± 0.60 (6/240) preoperatively to 0.41 ± 0.52 (6/15²). Mean logMAR best spectacle‐corrected visual acuity improved from 0.32 ± 0.15 (6/12) preoperatively to 0.10 ± 0.11 (6/7.5). Anisometropia improved from a difference of 6.37 ± 2.59 D preoperatively to 2.09 ± 1.37 D postoperatively, and there were no complications. Conclusion: Our technique for this clinical indication shows that the Visian Implantable Collamer Lens is a safe and effective alternative for treating post‐keratoplasty anisometropia.     

Combined endothelial keratoplasty and clear lens extraction for corneal decompensation in irido-corneal endothelial syndrome

A 38-year-old woman presented with corneal decompensation in left eye secondary to irido-corneal endothelial (ICE) syndrome. She underwent simultaneous Descemet''s stripping endothelial keratoplasty (DSEK) and clear lens extraction with posterior chamber intraocular lens implantation. The surgery was accomplished comfortably without rupture of peripheral anterior synechiae (PAS). 5 weeks postoperatively, the graft was attached, the cornea was clear and best-corrected visual acuity improved from 20/400 to 20/30. DSEK combined with clear lens extraction appears to be an effective measure to treat corneal decompensation in patients with ICE syndrome. Associated lens extraction in such cases increases the working space in anterior chamber for DSEK, which minimizes the intra-operative graft manipulation. This also avoids a future difficult cataract surgery in the presence of PAS and an endothelial graft, which may increase the chances of graft survival.     

Posterior chamber phakic intraocular lens implantation for high myopia

AIM:To evaluate the efficacy, safety and stability of posterior chamber phakic intraocular lens implantation for the correction of high myopia.METHODS: Retrospective case review of 82 eyes (43 patients) undergoing implantable Collamer lens (ICL) placement by a single surgeon (Xiao-Wei Gao) to correct preoperative mean spherical equivalents between -9.00 diopter (D) and -23.00D. Main outcome measures included uncorrected visual acuity (UCVA), refraction, best spectacle-corrected visual acuity (BSCVA), endothelial cell density (ECD), intraocular pressure (IOP), lens transparency, postoperative uveitis. Visante anterior segment optical coherence tomography (AS-OCT) was used to measure anterior chamber depth (ACD) and the position of ICL.RESULTS:Mean follow-up was 6.54±3.26 months (range 3-12 months). Predictability of the manifest spherical equivalent (SE) refraction to within ±1.00D was achieved in 88% of eyes and ±0.50D in 72.5% of eyes. The mean postoperative manifest SE refraction was -1.85±0.72D, with 96.34% of eyes maintaining or gaining ≥1 line(s) of BSCVA. The mean 3-month postoperative ECD decreased but had no statistically difference compared with the preoperative ECD. Of the 7 eyes (8.54%) with a mild transient increase in intraocular pressure (up to 30mmHg), none required a second surgical procedure or prolonged topical medication. There was no loss of lens transparency. Pigmented precipitates were observed in 5 eyes (6.09%). The mean preoperative ACD measured with AS-OCT was 3.28±0.14mm, three months after surgery, the mean ACD was 2.45±0.22mm. Anterior chamber depth showed a statistically significant reduction. One eye (1.22%) had ICL spontaneous rotation, 81 eyes (98.78%) of the lens remained correctly centered.CONCLUSION: The implantation of ICL is an effective surgical option for the management of high myopia. But its long time effect and safety still need more time to prove.     

有晶状体眼虹膜夹前房型人工晶状体植入矫治高度近视

有晶状体眼虹膜夹前房型人工晶状体植入矫治高度近视是矫治高度近视的一种新方法,因有良好的术后视觉质量、保留调节力、潜在的可逆性等优点,在国内已进入临床应用阶段。本文就此种晶状体的发展历史、该技术安全性、有效性、可预测性、准确性、稳定性,及其展望作一综述。     

传导性角膜成形术后眼压及角膜内皮细胞的变化

目的 探讨传导性角膜成形术（CK）对眼压和角膜内皮细胞的影响。方法 对20例（36眼）接受CK治疗的患者，于术前和术后第4周分别用非接触式眼压计（NCT）和Goldmann眼压计（GAT）测量眼压，行角膜内皮镜检查，观察中央区角膜内皮细胞形态和密度的变化。结果 和术前比较，术后眼压显著降低。眼压变化和年龄、性别、角膜曲率以及拟矫正屈光度无关。角膜内皮细胞形态和密度无显著性改变。结论 CK手术对角膜内皮细胞无损伤，不会造成角膜内皮细胞形态改变和密度降低。但术后压平式眼压计和非接触式眼压计测量眼压值偏低。为避免CK术后青光眼的误诊，不能按传统的正常眼压值衡量术后结果。     

AcrySof phakic angle-supported intraocular lens for the correction of high to extremely high myopia: one-year follow-up results

AIM: To assess the safety, efficacy and predictability of the AcrySof phakic angle-supported intraocular lens (IOL) (Alcon Inc., U.S.A.) for correction of high-to-extremely high myopia in adults.METHODS: In this prospective study performed in Tianjin Medical University Eye Center & College of Optometry, Tianjin, China, 25 eyes of 13 patients were implanted with AcrySof phakic angle-supported IOLs and followed for 1 year postoperatively. Preoperative manifest refractive sphere was (-12.08±2.44) diopters (D) and cylinder was (-1.35±0.62)D. Visual acuity, predictability and stability of manifest refraction spherical equivalent (MRSE), adverse events, and endothelial cell density were analyzed during 1-year of follow-up.RESULTS: After 1 year of follow-up, no eyes lost≥1 line (best spectacle-corrected visual acuity)BSCVA; an uncorrected visual acuity (UCVA) of 20/20 or better was achieved in 60% of eyes; 100% had an UCVA of 20/40 or better; a BSCVA of 20/30 or better was achieved by 100% of eyes; 84% had a BSCVA of 20/20 or better. The overall mean percentage change in endothelial cell density 1 year after surgery was (-0.27±3.60)%. Two eyes (8%) had increased intraocular pressure (IOP) on the day of surgery. No pupil ovalization, pupillary block, or retinal detachment events were observed.CONCLUSION: After 1 year of follow-up, the implantation of AcrySof phakic angle-supported IOL is proved to be safe, effective and predictable with minimal complications in patients with high-to-extremely high myopia. Due to the limitation of visiting time, long-term of clinical investigation is necessary to verify the safety and efficacy of this IOL.     

AcrySof phakic angle-supported intraocular lens for the correction of high to extremely high myopia: one-year follow-up results

AIM: To assess the safety, efficacy and predictability of the AcrySof phakic angle-supported intraocular lens (IOL) (Alcon Inc., U.S.A.) for correction of high-to-extremely high myopia in adults. METHODS: In this prospective study performed in Tianjin Medical University Eye Center & College of Optometry, Tianjin, China, 25 eyes of 13 patients were implanted with AcrySof phakic angle-supported IOLs and followed for 1 year postoperatively. Preoperative manifest refractive sphere was (-12.08±2.44) diopters (D) and cylinder was (-1.35±0.62)D. Visual acuity, predictability and stability of manifest refraction spherical equivalent (MRSE), adverse events, and endothelial cell density were analyzed during 1-year of follow-up. RESULTS: After 1 year of follow-up, no eyes lost≥1 line (best spectacle-corrected visual acuity)BSCVA; an uncorrected visual acuity (UCVA) of 20/20 or better was achieved in 60% of eyes; 100% had an UCVA of 20/40 or better; a BSCVA of 20/30 or better was achieved by 100% of eyes; 84% had a BSCVA of 20/20 or better. The overall mean percentage change in endothelial cell density 1 year after surgery was (-0.27±3.60)%. Two eyes (8%) had increased intraocular pressure (IOP) on the day of surgery. No pupil ovalization, pupillary block, or retinal detachment events were observed. CONCLUSION: After 1 year of follow-up, the implantation of AcrySof phakic angle-supported IOL is proved to be safe, effective and predictable with minimal complications in patients with high-to-extremely high myopia. Due to the limitation of visiting time, long-term of clinical investigation is necessary to verify the safety and efficacy of this IOL.     

有晶状体眼人工晶状体的研究进展

有晶状体眼人工晶状体(pIOL)按植入部位分为房角支撑型、虹膜固定型和后房型三种类型.随着材料和设计的改进,产品不断更新换代,由不可折叠变为可折叠,手术切口缩小,术后视觉效果改善,并发症相对减少.了解三种类型pIOL的发展过程和优缺点有助于医师根据患者条件及pIOL参数选择合适的人工晶状体.本文综述了pIOL的发展史及目前临床常用三种类型代表Acry-Sof、Artiflex/Veriflex、ICL的应用情况.     

有晶状体眼后房型人工晶状体植入术后的视觉质量

对有晶状体眼植入后房型人工晶状体是矫正屈光不正的有效方法,植入的后房型人工晶状体目前主要有可植入式接触镜(implantable contact lens,ICL)和有晶状体眼屈光性晶状体(phakic refractive lens,PRL)。对术后患者主观视觉质量(视力、对比敏感度)、客观视觉质量(波前像差、点扩散函数、斯特尔比率及光学传递函数)的研究显示,主观视力的提高也伴随着客观视觉质量的改善,但部分患者术后出现光晕及眩光症状。本文主要对ICL和PRL植入术后主观及客观视觉质量的临床研究做一综述,对可影响视觉质量的术后并发症如晶状体前囊膜下混浊、青光眼及角膜内皮功能异常等需进一步远期随访。     

Verisyse虹膜固定型人工晶状体植入治疗高度近视的中长期疗效观察

目的:研究Verisyse虹膜固定型人工晶状体植入治疗高度近视中长期的有效性和安全性。方法:高度近视患者37例56眼植入Verisyse虹膜固定型人工晶状体,术后随访4～7a,对手术前后的裸眼和最佳矫正视力、屈光状态、眼压变化、角膜透明度及角膜内皮计数、前房、瞳孔和虹膜、自然晶状体改变及患者满意度进行观察分析。结果:所有眼术中均顺利植入Verisyse虹膜固定型人工晶状体,术后各时间点裸眼视力及最佳矫正视力均明显提高且保持稳定,各时间点角膜内皮细胞计数变化无统计学意义,随访期间无角膜内皮失代偿、顽固的色素膜炎、白内障、青光眼及视网膜脱离等严重并发症发生。结论:Verisyse虹膜固定型人工晶状体治疗高度近视是安全和有效的,能够显著提高裸眼视力及最佳矫正视力而并发症较少,对于不适合角膜手术的高度或超高度近视患者是一种比较理想的选择。     

有晶状体眼后房型人工晶状体植入矫正中高度散光

目的评价有晶状体眼后房型人工晶状体植入矫正中高度散光的有效性、安全性及稳定性。方法选取高度散光105例（187眼）,植入带散光的后房型人工晶状体。随访观察3～36个月。结果裸眼视力均有明显提高,3个月后裸眼视力≥术前最佳矫正视力者182眼占97.33%,散光度数在±1.00D以内者占91.27%,残留散光平均为（-0.56±0.3）D,矫正者占89.72%,术前与术后差异有统计学意义（P〈0.01）。术后2眼（1.07%）发生晶状体前囊下浑浊。结论有晶状体眼后房型人工晶状体植入矫正中高度散光具有有效性、安全性及稳定性。     

有晶状体眼人工晶状体植入术研究进展

屈光手术的种类繁多，针对各种屈光不正，均有不同的手术方式。然而对于高度屈光不正，有晶状体眼人工晶状体(phakic intraocular lens，PIOL)植入术显示了其独特的优越性。PIOL植入术的发展历史、晶状体类型、手术方法、常见并发症等，在以往的综述中都阐述较多。本文就PIOL设计和材料的改进、主要并发症及其预防措施、新出现的并发症及治疗方法、PIOL植入术的其他应用作一综述。     

Artisan有晶状体眼人工晶状体植入术后远期角膜内皮细胞的变化

背景 Artisan有晶状体眼人工晶状体(pIOL)植入矫正高度近视术后早期是安全、有效的,由于人工晶状体位于前房,术后对角膜内皮的影响值得关注. 目的 研究Artisan pIOL矫正高度近视术后角膜内皮细胞密度(ECD)和形态的长期变化.方法 对2005年1月至2008年12月在广东省人民医院眼科行Artisan pIOL植入术的高度近视27例51眼进行回顾性分析,采用角膜内皮计数仪测定角膜中央区的角膜ECD,评估计算细胞面积变异系数(CV)和细胞面积标准差(SD),比较并分析术前和术后6个月及1、2、3、4、5、6年上述各指标的变化,计算ECD丢失率[(术前ECD-术后ECD)/术前ECD× 100％]. 结果 术后6年时,34眼BCVA≥1.0,14眼BCVA较术前提高,8眼BCVA较术前降低;平均眼压为(14.23±2.14) mmHg.术眼术前平均ECD为(3 184.05±.233.55)/mm2,术后6个月及术后1、2、3、4、5、6年ECD平均丢失率分别为2.34％、5.32％、6.32％、8.06％、12.59％、15.63％和19.49％.术眼术前细胞面积CV和细胞面积SD分别为37.17±7.12和118.77±21.39,术后6年时分别为32.24±4.62和125.60±18.49.不同时间点细胞面积CV和SD总体比较,差异均有统计学意义(P=0.000、0.036).术眼术后出现局限性虹膜色素脱失者8眼,发生IOL偏位者6眼,术后1个月出现一过性高眼压者3眼,出现黄斑出血者2眼. 结论 Artisan pIOL植入术后随着时间推移ECD逐渐下降,且角膜内皮细胞形态进行重构,增加了细胞的稳定性,因此Artisan pIOL术后对术眼角膜内皮细胞的长期影响值得关注.     

有晶状体眼前房型人工晶状体植入治疗高度近视远期安全性与稳定性的评估

目的:观察有晶状体眼前房型人工晶状体植入治疗高度近视远期的安全性与稳定性。方法:对近视屈光度为-7.00～-23.00D的42例(80眼)高度近视患者行有晶状体眼前房房角支撑袢型人工晶状体植入术,对连续观察1a以上平均时间18mo的患者进行裸眼视力,屈光状态,角膜内皮细胞计数、眼压、房角状况、虹膜、瞳孔、晶状体以及眼底情况的观察并t检验分析。结果:80眼均成功植入前房型人工晶状体,无1例取出。裸眼视力术前0.02～0.08,术后18mo0.15～1.2,最佳矫正视力术前0.15～1.0,术后0.25～1.2;术后18mo时最佳矫正视力均好于或等于术前,眼压差异无显著意义(t=1.09,P=0.276);平均角膜内皮细胞计数术前为2979±293个/mm2,术后18mo2 843±443个/mm2,下降率为4.67%,差异无显著意义(t=1.12,P=0.263);无白内障、房角粘连及新生血管发生。结论:采用有晶状体眼前房型人工晶状体植入术矫正高度近视术后疗效好,视力恢复快,屈光状态稳定,可预测,可逆,无严重并发症发生。     

有晶状体眼前房型人工晶状体植入矫治高度近视临床观察

目的:观察有晶状体眼Verisyse前房虹膜夹型人工晶状体植入矫治高度近视术后的视力、屈光状态以及相关并发症,评价其临床应用价值。方法:自2006-07/2008-07接受Verisyse人工晶状体植入术的32例48眼,术前平均球镜当量-15.65±3.41D。统计术后6mo;1a裸眼视力,最佳矫正视力、屈光度、内皮细胞计数,分析并发症的发生情况。结果:术后裸眼视力:0.4～1.0,平均0.75±0.34。术前最佳矫正视力:0.3～1.0,平均0.58±0.27,术后最佳矫正视力0.64±0.30。达到术前矫正42眼(87.5%),超过术前最佳矫正视力14眼(29.2%),随访6mo;1a,无明显变化。术前屈光平均球镜当量-15.65±3.41D;术后屈光度数平均球镜当量-1.58±2.47D。角膜内皮细胞计数术前(3108±265)个/mm2,术后6mo为(3054±317)个/mm2,差异无统计学意义。未见威胁视力的并发症。结论:有晶状体眼前房虹膜夹型人工晶状体植入矫治超高度近视安全有效,术后屈光效果令人满意。对眼内的长期影响需要进一步观察。     

Five-year endothelial cell count post penetrating keratoplasty using internationally-transported corneal donor tissue

Aim

To study the five-year endothelial cell loss in patients having undergone penetrating keratoplasty (PKP) and who received corneal donor tissue from international eye banks.

有晶状体眼前房角固定型人工晶状体植入术的进展

有晶状体眼前房角固定型人工晶状体植入术是近年来发展起来的矫正高度和超高度近视的一项新技术，随着晶状体材料的改良和临床经验的积累，这种屈光手术逐渐显示出了安全、有效、预测性好、可逆性、保留调节功能和对角膜内皮损伤小等优点。因此，在未来的几年里，前房角固定型人工晶状体植入术作为一种屈光手术将会扩大它的临床应用范围。就该手术的历史、人工晶状体的设计、手术适应证与禁忌证、手术技术、并发症及其防治等方面进行综述。     

有晶状体眼后房型人工晶状体植入术矫正高度近视

探讨有晶状体眼后房型人工晶状体（phakic intraocular lens,PIOL）植入术矫正高度近视的有效性和安全性。 方法：本研究中高度近视患者17例33眼,术前屈光度-8.00～-24.00 (平均-15.46±6.26)D,眼轴长度25.33～33.77(平均30.22±2.55)mm。33眼植入后房型人工晶状体也称植入性接触镜（implantable contact lens,ICL& toric implantable collamer lens, TICL）。其中,22眼植入ICL,11眼植入TICL。术后观察视力、屈光度、眼压、人工晶状体位置等。 结果：所有病例均成功植入后房型人工晶状体。术后1wk,所有手术眼达到或超过术前最佳矫正视力,屈光度和眼压稳定。 结论：有晶状体眼后房型人工晶状体植入术治疗高度近视安全有效,适用屈光度范围广,术后屈光度稳定,视觉质量提高     

Comparison of patient outcomes after implantation of Visian toric implantable collamer lens and iris-fixated toric phakic intraocular lens

Purpose

We compared visual and refractive outcomes after implantation of Visian toric implantable collamer lenses (toric ICLs) and iris-fixated toric pIOLs (toric Artisans).

Patients and methods

A comparative retrospective analysis was performed. Toric ICLs were implanted into 30 eyes of 18 patients, and toric Artisans into 31 eyes of 22 recipients. We measured the logarithms of the minimum angle of resolution of uncorrected visual acuity (logMAR UCVA), logMAR of best spectacle-corrected corrected VA (logMAR BSCVA), MR, SE, and astigmatism (by the power vector method) before surgery and 1, 3, and 6 months thereafter. Differences between patients receiving each type of lens were compared by using a mixed model of repeated measures.

Results

Visual improvements were evident after operation in both groups. By comparing the attempted to the achieved SE values, we were able to confirm that correction of refractive error was similar in both groups. However, the logMAR UCVA was significantly higher in the toric ICL group at all postoperative time points. Although manifest cylinder power and astigmatism (calculated by using the power vector method) gradually decreased in the toric ICL group, cylinder power 1 month postoperatively increased from −2.62 to −2.75 D; astigmatism was also increased at this time in the toric Artisan group.

Conclusion

The two tested toric pIOLs were similar in terms of the ability to correct refractive error, as assessed 3 months postoperatively. However toric ICLs corrected astigmatism more rapidly and safely. Notably, the large difference in astigmatism level between the two groups 1 month postoperatively indicates that toric ICLs are more effective when used to correct astigmatism.     

有晶状体眼虹膜固定型人工晶状体植入矫正高度近视的临床研究

目的探讨有晶状体眼虹膜固定型人工晶状体植入矫正高度近视的有效性、安全性和可预测性。方法对屈光度为-8.25～-28.00D的32例（53眼）高度近视患者行有晶状体眼Verisyse人工晶状体植入术。手术前、后观察患者的视力、屈光度数、眼压、角膜内皮细胞计数及并发症,术后随访时间6个月。结果53眼均成功植入Verisyse人工晶状体。术后第6个月时,患者裸眼视力≥4.7者占100%,最佳矫正视力≥4.9者占84.9%,裸眼视力和最佳矫正视力均较术前明显提高,差异具有统计学意义;90.6%患者术后屈光度在预期的±1.0D之内;眼压、角膜内皮计数与术前相比,差异均无统计学意义（P〉0.05）。手术无严重并发症发生。结论有晶状体眼虹膜固定型人工晶状体植入矫正高度近视具有较好的有效性、安全性和可预测性,无严重并发症发生,但其远期效果有待于进一步观察。